Sacral Neuromodulation System Treats Urinary and Fecal Dysfunction

A novel rechargeable, implantable, sacral neuromodulation (SNM) system helps in the treatment of overactive bladder (OAB), fecal incontinence, and urinary retention.

The Axonics SNM System helps in the management of urinary and fecal dysfunction by modulating the sacral nerve, which controls everyday function of the pelvic floor, urethral sphincter, bladder, and bowel. The system includes a miniaturized implantable pulse generator that promises to last 15 years, more than three times longer than currently marketed non-rechargeable SNM devices. In addition, the system features a patient-friendly remote control and an intuitive clinician programmer that guides and supports physician implanters throughout the procedure, from lead placement to programming.

The system works by imitating a signal sent via the central nervous system (CNS) when the nerves in the sacral area and the brain no longer communicate effectively, resulting in a bowel/bladder disorder. By stimulating the sacral nerve, a signal is sent that manipulates a contraction within the pelvic floor. Over time these contractions rebuild the strength of the organs and muscles, alleviating or eliminating symptoms of the urinary/fecal disorder. The Axonics SNM System is a product of Axonics Modulation Technologies (Irvine, CA, USA), and has received the European Community CE mark of approval.

“Axonics has successfully developed a unique product to deliver SNM therapy that we believe will greatly improve the patient and clinician experience,” said Raymond Cohen, CEO of Axonics. “We look forward to treating patients in our upcoming post-market clinical follow up (PMCF) study.”

“The Axonics device promises increased patient comfort given its small size and moreover, the fact that it is rechargeable and can function three times longer in patients will eliminate the need for repeat surgeries to replace non-rechargeable devices that currently require replacement every four or five years,” said Professor Karen Noblett, MD, of the University of California Riverside (UCR; USA) School of Medicine.

OAB affects more than 37 million people in the United States alone, with a significant impact on the quality of life of suffers by affecting social activities, disrupting exercise, and causing disruptive nighttime voiding. Despite this, only 33% of those suffering seek treatment, and as many as 70% stop using their medication within six months, due to intolerable side effects or unsatisfying results.

Related Links:
Axonics Modulation Technologies
University of California Riverside